When esophageal candidiasis fails to improve after an adequate course of fluconazole, a different treatment strategy is required. This protocol covers that next clinical step.

Escalation Trigger — Prior Treatment Failure

First-line treatment was oral fluconazole. Escalation to this protocol is indicated when improvement or resolution of esophageal candidiasis symptoms has not occurred within 7 days of starting that regimen — defining fluconazole-refractory disease.

Next-Line Approach

For fluconazole-refractory esophageal candidiasis, the evidence supports several alternative antifungal strategies across different drug classes. The full structured protocol details the specific agents, selection criteria, and duration for each option.

References

For fluconazole-refractory disease, itraconazole solution, 200 mg daily, OR voriconazole, 200 mg (3 mg/kg) twice daily either intravenous or oral, for 14–21 days is recommended.

Alternatives for fluconazole-refractory disease include an echinocandin (micafungin: 150 mg daily; caspofungin: 70-mg loading dose, then 50 mg daily; or anidulafungin: 200 mg daily) for 14–21 days, OR AmB deoxycholate, 0.3–0.7 mg/kg daily, for 21 days.

Posaconazole suspension, 400 mg twice daily, or extended-release tablets, 300 mg once daily, could be considered for fluconazole-refractory disease.

DOI: 10.1093/cid/civ933

View source ↗

Esophageal Candidiasis Not Responding to Fluconazole